<DOC>
	<DOCNO>NCT02235519</DOCNO>
	<brief_summary>The goal study build mathematical model explain effect two dos azilsartan ( 40 80 mg ) upon metabolic ( insulin resistance , glucose ) inflammatory parameter ( cytokine ) function `` metabolic stratum '' like obesity , type 2 diabetes mellitus , hypertension combination .</brief_summary>
	<brief_title>Pleiotropic Effects Azilsartan Medoxomil Over Insulin Resistance Obese , Diabetic Hypertensive Patients</brief_title>
	<detailed_description>There data support angiotensin II receptor subtype 1 ( AT1 ) antagonist beneficial effect metabolic control due pleiotropic effect mediate peroxisome proliferator-activated receptor ( PPAR ) gamma induction . Azilsartan prodrug absorb gastrointestinal tract improve metabolic milieu diverse condition like obesity , hypertension ( consider metabolic disease ) type 2 diabetes mellitus . Clinical study raise regard , still show controversial issue . The objective study AT1 antagonist drug interested pleiotropic effect focus antihypertensive improvement , also effect area metabolism lipid carbohydrates obese and/or type 2 diabetes . This study randomize , open label , clinical study . The aim build mathematical model support effect azilsartan 40 80 mg metabolic inflammatory measurement function metabolic condition ( i.e . obesity , type 2 diabetes hypertension , combination ) . Patients stratify accord metabolic status randomize block four stratum . This strategy help maintain treatment group balance . All subject receive treatment 12 week . Subjects attend outpatient consultation Hospital General de Mexico invite participate study . Those meet inclusion criterion must sign informed consent approve ethic committee . This document describe follow-up visit describe : Screening visit ( V-1 ) : This visit include patient history , physical examination ( weight , height , waist circumference blood pressure ) blood sample measurement : complete blood count , fast glucose , HbA1c , creatinine , adiponectin , IL-1b , IL-6 , IL-10 , TNF-α , liver function test , C-reactive protein , blood chemistry , proteinuria , 24-hours urinary glucose creatinine . Initial visit ( V0 ) : Physical examination perform blood sample oral glucose tolerance test drawn 0 , 30 , 60 , 90 120 minute , data point Matsuda insulin sensitivity index calculate . Pharmacological treatment 40mg 80mg azilsartan 4 week assign ( open label randomize ) . Visit 1 2 ( V1 , V2 ) : These visit perform 4 8 week respectively include : physical examination , record adverse event medication count check adherence treatment accomplishment . Visit 3 ( V3 ) : Week 12 include physical examination , adverse event registration , complete blood count , fast glucose , HbA1c , creatinine , adiponectin , IL-1b , IL-6 , IL-10 , TNF - α , liver function test , C reactive protein , blood chemistry , proteinuria , 24-hours urinary glucose creatinine . Furthermore oral glucose tolerance test sample 0 , 30 , 60 , 90 120 minute take , calculate index insulin sensitivity Matsuda method . Statistical analysis sample size . The sample size calculate ANCOVA analysis consider 8 group 5 covariates . Considering alpha error 5 % , effect size 30 % , statistical power 90 % total sample 250 patient calculate . If consider 20 % attrition sample , give total 300 patient , i.e . 150 patient per treatment group . A descriptive analysis do . The contrast among group analyze ANCOVA model function fitness calculate use ordinary least square . Dependent variable insulin sensitivity , proteinuria , stiffness carotid artery , cytokine . Fixed factor : sex , blood pressure category , metabolic status , drug treatment . Covariates : Age , waist circumference . The great expected size effect would within group patient obesity , hypertension , type 2 diabetes mellitus ( three ) treat 80 mg low size effect within group obesity treat 40 mg .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<criteria>1 . Written inform consent accordance Good Clinical Practices local legislation 2 . Age ≥25 ≤ 65 year 3 . Patients hypertension stage 1 define systolic blood pressure ( SBP ) ≥140 &lt; 159 mmHg diastolic blood pressure ( DBP ) ≥90 &lt; 99 mmHg randomization 4 . Ability stop current antihypertensive therapy without unacceptable risk patient ( Investigator 's discretion ) 5 . BMI ≥25 ≤35 . 6 . Patients type 2 diabetes mellitus participate stratified randomization . Diagnosis establish clinical history , 75g oral glucose tolerance test ( ADA criterion ) , fast glucose &gt; 126 mg/dL . 1 . Premenopausal woman ( last menstruation ≤1 year prior sign informed consent ) surgically sterile , nursing , pregnant without anticonceptive method . 2 . Known hypersensitivity study drug 3 . Gastrointestinal surgery might alter absorption , distribution , drug metabolism . 4 . History angioedema relate ACE inhibitor angiotensin II receptor blocker . 5 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 a.m. 6 . Known suspected secondary hypertension ( e.g. , renal artery stenosis phaeochromocytoma ) 7 . SBP≥160 mmHg and/or DBP ≥100 mmHg 8 . Renal dysfunction define : serum creatinine &gt; 3.0 mg/dL ( &gt; 265 umol/L ) and/or creatinine clearance &lt; 30 ml/min and/or clinical marker severe renal impairment . 9 . Bilateral renal arterial stenosis , renal artery stenosis solitary functional kidney , postrenal transplant patient patient one kidney 10 . Clinically relevant hypokalemia hyperkalemia ( i.e. , &lt; 3.5 mmol/L &gt; 5.5 mmol/L , may rechecked suspected error result ) 11 . Uncorrected sodium volume depletion 12 . Primary aldosteronism . 13 . Hereditary fructose intolerance 14 . Biliary obstructive disorder ( e.g. , cholestasis ) hepatic insufficiency 15 . Congestive heart failure class IIIIV accord criterion fron New York Heart Association . 16 . Clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine Investigator . 17 . Hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve 18 . Patients whose diabetes stable control least past 3 month define Glycosylated Hemoglobin A1c &gt; =10 % fast glucose great 400 mg/dL . 19 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensinII receptor antagonist 20 . History drug alcohol dependency within 6 month prior sign inform consent form 21 . Concomitant administration medication know affect blood pressure , except medication allow protocol 22 . Any investigational drug therapy within 1 month signing inform consent 23 . Known hypersensitivity component trial drug ( telmisartan , hydrochlorothiazide , placebo ) 24 . History noncompliance inability comply prescribed medication protocol procedure ( less 80 % 120 % , especially runin ) . 25 . Any clinical condition , opinion investigator , would allow safe completion protocol safe administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>